LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Thursday reported a loss of $13 million in its second quarter.

On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 41 cents.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 68 cents per share.

The biopharmaceutical company posted revenue of $6.4 million in the period.

Concert shares have climbed roughly 2% since the beginning of the year. The stock has declined 10% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNCE at https://www.zacks.com/ap/CNCE

Automated Insights, source Associated Press News